Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial

Table 2 Liver steatosis and fibrosis of patients at baseline and after 3 month (Mean values and standard deviations)

Characteristics	Baseline Mean ± SD	After 3 month Mean ± SD	P*	Change Mean ± SD	P^†
Fibrosis (kPa)
Cit	5.85 ± 1.71	5.84 ± 2.00	0.44	− 0.21 ± 1.18	0.8
Placebo	6.27 ± 2.08	6.12 ± 1.81	0.15	− 0.43 ± 1.15
Steatosis grade (0/1/2/3) ^‡
Cit	2.86 ± 0.35	2.44 ± 0.85	0.04	− 0.44 ± 0.85	0.8
Placebo	2.62 ± 0.66	2.38 ± 0.88	0.13	− 0.37 ± 0.95
Steatosis (dB/m)
Cit	320.8 ± 29.6	304.5 ± 39.1	0.127	− 16.33 ± 43.18	0.97
Placebo	315.5 ± 36.8	299.6 ± 45.7	0.171	− 15.87 ± 44.19

* P values indicate comparison within groups
^†P values indicate comparison between the changes of each variable between two groups
^‡According to ultrasound exam

ISSN: 1756-0500